ABUS
Price
$3.48
Change
+$0.08 (+2.35%)
Updated
Jun 6 closing price
Capitalization
652.15M
53 days until earnings call
DNLI
Price
$14.70
Change
+$0.48 (+3.38%)
Updated
Jun 6 closing price
Capitalization
2.07B
53 days until earnings call
Interact to see
Advertisement

ABUS vs DNLI

Header iconABUS vs DNLI Comparison
Open Charts ABUS vs DNLIBanner chart's image
Arbutus Biopharma
Price$3.48
Change+$0.08 (+2.35%)
Volume$557.51K
Capitalization652.15M
Denali Therapeutics
Price$14.70
Change+$0.48 (+3.38%)
Volume$1.79M
Capitalization2.07B
ABUS vs DNLI Comparison Chart
Loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABUS vs. DNLI commentary
Jun 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Hold and DNLI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 08, 2025
Stock price -- (ABUS: $3.41 vs. DNLI: $13.04)
Brand notoriety: ABUS and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 71% vs. DNLI: 82%
Market capitalization -- ABUS: $652.15M vs. DNLI: $2.07B
ABUS [@Biotechnology] is valued at $652.15M. DNLI’s [@Biotechnology] market capitalization is $2.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • ABUS’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, ABUS is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 5 TA indicator(s) are bullish while DNLI’s TA Score has 3 bullish TA indicator(s).

  • ABUS’s TA Score: 5 bullish, 4 bearish.
  • DNLI’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ABUS is a better buy in the short-term than DNLI.

Price Growth

ABUS (@Biotechnology) experienced а +7.57% price change this week, while DNLI (@Biotechnology) price change was -4.75% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

ABUS is expected to report earnings on Jul 31, 2025.

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.07B) has a higher market cap than ABUS($652M). ABUS YTD gains are higher at: 4.281 vs. DNLI (-36.016). ABUS has higher annual earnings (EBITDA): -75.14M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. ABUS (128M). ABUS has less debt than DNLI: ABUS (1.45M) vs DNLI (48.7M). ABUS has higher revenues than DNLI: ABUS (6.74M) vs DNLI (0).
ABUSDNLIABUS / DNLI
Capitalization652M2.07B32%
EBITDA-75.14M-492.89M15%
Gain YTD4.281-36.016-12%
P/E RatioN/AN/A-
Revenue6.74M0-
Total Cash128M832M15%
Total Debt1.45M48.7M3%
FUNDAMENTALS RATINGS
ABUS vs DNLI: Fundamental Ratings
ABUS
DNLI
OUTLOOK RATING
1..100
665
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
61100
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
5290
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABUS's Valuation (67) in the Biotechnology industry is in the same range as DNLI (93). This means that ABUS’s stock grew similarly to DNLI’s over the last 12 months.

ABUS's Profit vs Risk Rating (61) in the Biotechnology industry is somewhat better than the same rating for DNLI (100). This means that ABUS’s stock grew somewhat faster than DNLI’s over the last 12 months.

DNLI's SMR Rating (95) in the Biotechnology industry is in the same range as ABUS (98). This means that DNLI’s stock grew similarly to ABUS’s over the last 12 months.

ABUS's Price Growth Rating (52) in the Biotechnology industry is somewhat better than the same rating for DNLI (90). This means that ABUS’s stock grew somewhat faster than DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as ABUS (100). This means that DNLI’s stock grew similarly to ABUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSDNLI
RSI
ODDS (%)
N/A
Bearish Trend 11 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 11 days ago
86%
Bullish Trend 11 days ago
75%
Momentum
ODDS (%)
Bullish Trend 11 days ago
72%
Bearish Trend 11 days ago
81%
MACD
ODDS (%)
Bullish Trend 11 days ago
79%
Bearish Trend 11 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
77%
Bearish Trend 11 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
76%
Bearish Trend 11 days ago
85%
Advances
ODDS (%)
Bullish Trend 19 days ago
78%
Bullish Trend 19 days ago
78%
Declines
ODDS (%)
Bearish Trend 23 days ago
79%
Bearish Trend 11 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
86%
N/A
Aroon
ODDS (%)
Bullish Trend 11 days ago
77%
Bullish Trend 11 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with IDYA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
-1.16%
IDYA - ABUS
46%
Loosely correlated
+0.72%
DNLI - ABUS
44%
Loosely correlated
-1.29%
VTYX - ABUS
41%
Loosely correlated
+0.57%
KRYS - ABUS
41%
Loosely correlated
-2.44%
IMVT - ABUS
41%
Loosely correlated
-1.33%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-1.29%
BEAM - DNLI
61%
Loosely correlated
-0.88%
RCKT - DNLI
59%
Loosely correlated
+6.44%
NTLA - DNLI
59%
Loosely correlated
+3.59%
ARWR - DNLI
58%
Loosely correlated
+1.24%
RGNX - DNLI
58%
Loosely correlated
-5.84%
More